BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 29549624)

  • 21. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma.
    Li G; Zhao A; Péoch M; Cottier M; Mottet N
    Urol Oncol; 2017 May; 35(5):294-299. PubMed ID: 28089386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffusion-weighted imaging using 3.0 T MRI as a possible biomarker of renal tumors.
    Mirka H; Korcakova E; Kastner J; Hora M; Hes O; Hosek P; Ferda J
    Anticancer Res; 2015 Apr; 35(4):2351-7. PubMed ID: 25862900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
    Amin J; Xu B; Badkhshan S; Creighton TT; Abbotoy D; Murekeyisoni C; Attwood KM; Schwaab T; Hendler C; Petroziello M; Roche CL; Kauffman EC
    Clin Cancer Res; 2018 Aug; 24(16):3898-3907. PubMed ID: 29752278
    [No Abstract]   [Full Text] [Related]  

  • 24. Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma.
    Fedorko M; Juracek J; Stanik M; Svoboda M; Poprach A; Buchler T; Pacik D; Dolezel J; Slaby O
    Biochem Med (Zagreb); 2017 Jun; 27(2):411-417. PubMed ID: 28694731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?
    Ng KL; Del Vecchio SJ; Samaratunga H; Morais C; Rajandram R; Vesey DA; Wood ST; Gobe GC
    Pathology; 2018 Aug; 50(5):504-510. PubMed ID: 29970253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic test accuracy of ADC values for identification of clear cell renal cell carcinoma: systematic review and meta-analysis.
    Tordjman M; Mali R; Madelin G; Prabhu V; Kang SK
    Eur Radiol; 2020 Jul; 30(7):4023-4038. PubMed ID: 32144458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E.
    Li G; Chong T; Xiang X; Yang J; Li H
    Oncol Rep; 2017 Oct; 38(4):1995-2002. PubMed ID: 28849086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma.
    Cornejo KM; Lu M; Yang P; Wu S; Cai C; Zhong WD; Olumi A; Young RH; Wu CL
    Hum Pathol; 2015 Jun; 46(6):820-6. PubMed ID: 25827535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications.
    Kruck S; Hennenlotter J; Vogel U; Schilling D; Gakis G; Hevler J; Kuehs U; Stenzl A; Schwentner C
    BJU Int; 2012 Feb; 109(4):634-8. PubMed ID: 21711439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of the Peritumoral Pseudocapsule Vary Predictably With Histologic Subtype of T1 Renal Neoplasms.
    Jacob JM; Williamson SR; Gondim DD; Leese JA; Terry C; Grignon DJ; Boris RS
    Urology; 2015 Nov; 86(5):956-61. PubMed ID: 26126697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.
    Kauffman EC; Barocas DA; Chen YT; Yang XJ; Scherr DS; Tu JJ
    J Urol; 2009 May; 181(5):2305-11. PubMed ID: 19303095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma.
    Kaneko S; Matsumoto K; Minamida S; Hirayama T; Fujita T; Kodera Y; Iwamura M
    Asian Pac J Cancer Prev; 2016; 17(3):1399-404. PubMed ID: 27039779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma.
    Zhang W; Ni M; Su Y; Wang H; Zhu S; Zhao A; Li G
    Eur Urol Focus; 2018 Apr; 4(3):412-419. PubMed ID: 28753793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.
    Young JR; Coy H; Kim HJ; Douek M; Lo P; Pantuck AJ; Raman SS
    AJR Am J Roentgenol; 2017 Apr; 208(4):812-819. PubMed ID: 28125273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.
    Young JR; Margolis D; Sauk S; Pantuck AJ; Sayre J; Raman SS
    Radiology; 2013 May; 267(2):444-53. PubMed ID: 23382290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.
    Han WK; Alinani A; Wu CL; Michaelson D; Loda M; McGovern FJ; Thadhani R; Bonventre JV
    J Am Soc Nephrol; 2005 Apr; 16(4):1126-34. PubMed ID: 15744000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNAs as Urinary Biomarker for Oncocytoma.
    von Brandenstein M; Schlosser M; Herden J; Heidenreich A; Störkel S; Fries JWU
    Dis Markers; 2018; 2018():6979073. PubMed ID: 30116406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary exosome miR-30c-5p as a biomarker of clear cell renal cell carcinoma that inhibits progression by targeting HSPA5.
    Song S; Long M; Yu G; Cheng Y; Yang Q; Liu J; Wang Y; Sheng J; Wang L; Wang Z; Xu B
    J Cell Mol Med; 2019 Oct; 23(10):6755-6765. PubMed ID: 31342628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.